Bristol-Myers suses Dr. Reddy's for patent infringement in US

摘要

US-based drug maker, Bristol-Myers Squibb Company (BMS) has filed a patent infringement case against Dr. Reddy's Laboratories (DRL) over the cancer drug 'Ixempra'. BMS in its petition filed in the United States District Court of New Jersey alleged that Dr. Reddy's has infringed the patents of its drug on three counts. According to the petition, by a letter dated November 13, 2012, DRL notified Bristol-Myers that the Indian drug major had submitted Abbreviated New Drug Application (ANDA) concerning its proposed drug product of Ixabepilone for injection, as required by the FDA rules.